GRIN2C

Glutamate receptor ionotropic, NMDA 2C · Q14957 · GRIN2C on Sugi Atlas →

109,698 patent compounds predicted against GRIN2C, 62,767 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Ditolylguanidine (SCHEMBL80339)	1.00	14/20
SCHEMBL123451	0.55	14/20
SCHEMBL121942	1.00	11/20
Guanabenz (SCHEMBL15390)	0.65	11/20
Memantine (SCHEMBL2688)	1.00	9/20
Memantine (SCHEMBL2689)	1.00	9/20
Memantine (SCHEMBL3053)	0.95	9/20
Levorphanol (SCHEMBL24335)	1.00	8/20
Racemorphan (SCHEMBL46201)	1.00	8/20
Dextrorphan (SCHEMBL115577)	1.00	8/20
SCHEMBL103596	0.44	8/20
Dextromethorphan (SCHEMBL29949)	1.00	7/20
Levomethorphan (SCHEMBL29950)	1.00	7/20
SCHEMBL78658	1.00	7/20
Radiprodil (SCHEMBL99256)	1.00	7/20
Racemethorphan (SCHEMBL118520)	1.00	7/20
Dextromethorphan (SCHEMBL121924)	0.98	7/20
Dextrorphan (SCHEMBL122564)	0.98	7/20
Dextromethorphan (SCHEMBL121923)	0.95	6/20
Levorphanol (SCHEMBL120616)	0.82	6/20

Clinical trials — most relevant to GRIN2C by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine	PHASE4	COMPLETED
PCA Ketamine-Morphine VS PCA Morphine as Post-Operative Analgesia in Colorectal Surgery.	PHASE4	COMPLETED
TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders	PHASE3	RECRUITING
Memantine for Refractory OCD Patients	PHASE3	UNKNOWN
A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial	PHASE2/PHASE3	NOT_YET_RECRUITING
Prehospital Early Administration of Ketamine for Status Epilepticus in Epileptic Kids (PEAK-SEEK)	PHASE2/PHASE3	RECRUITING
A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease	PHASE3	COMPLETED
Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder	PHASE2	COMPLETED
Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia	PHASE2	COMPLETED
Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders	PHASE2	COMPLETED
High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia	PHASE2	UNKNOWN
NMDA Modulation in Major Depressive Disorder	PHASE2	RECRUITING
Antidepressant Effects of NR2B in Major Depression	PHASE1	COMPLETED
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response	PHASE1	RECRUITING
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response, Pilot Trial	PHASE1	COMPLETED
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression	PHASE1	RECRUITING
Biomarkers of Fast Acting Therapies in Major Depression	PHASE1	COMPLETED
A Trial of Dextromethorphan for Treatment of Major Depressive Disorder	PHASE1	COMPLETED
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine	EARLY_PHASE1	COMPLETED
D-aspartate and Therapeutic Exercise	EARLY_PHASE1	UNKNOWN
Tolerability and Efficacy of L-Serine in Patients With GRIN-related Encephalopathy	nan	UNKNOWN
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease	nan	COMPLETED
Acamprosate: Genes Associated With Response	nan	COMPLETED
An Assessment of Cognitive Function in Irritable Bowel Syndrome	nan	UNKNOWN
Mechanisms of Human Plasticity in the Human System	nan	COMPLETED
PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX	nan	COMPLETED
The Neuroprotective Effect of Dexmedetomidine Preserving Brain Functional Connectivity in Elderly Patients	nan	COMPLETED
Effect of Dexmedetomidine Combined With Low-dose Nalmefene on Preventing Remifentanil-induced Postoperative Hyperalgesia	nan	COMPLETED
Effect of Butorphanol Combined With Flurbiprofen Axetil on Preventing Hyperalgesia Induced by Remifentanil in Patients	nan	COMPLETED
7 Tesla MRI Brain Imaging to Decipher Filgotinib's Mode of Analgesic Action in Rheumatoid Arthritis	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a GRIN2C binder may also engage these)

Protein	Name	Similarity
Q01098	—	1.000	Q01098 →
Q00961	—	1.000	Q00961 →
GRIN3A	Glutamate receptor ionotropic, NMDA 3A	0.976	landscape →
Q9R1M7	—	0.975	Q9R1M7 →
A2AIR5	—	0.975	A2AIR5 →
Q03391	—	0.965	Q03391 →
Q62645	—	0.963	Q62645 →
GRIN2D	Glutamate receptor ionotropic, NMDA 2D	0.962	landscape →
O54951	—	0.950	O54951 →
GRIN3B	Glutamate receptor ionotropic, NMDA 3B (GluN3	0.950	landscape →
Q9H3T3	—	0.949	Q9H3T3 →
O70141	—	0.948	O70141 →
Q96FT7	—	0.948	Q96FT7 →
Q8VHN2	—	0.947	Q8VHN2 →
Q7TNS7	—	0.947	Q7TNS7 →
Q91ZU9	—	0.946	Q91ZU9 →
Q9JHS6	—	0.944	Q9JHS6 →
Q9R1V4	—	0.940	Q9R1V4 →
Q3UHN9	—	0.940	Q3UHN9 →
P52848	—	0.940	P52848 →
Q9ESM2	—	0.939	Q9ESM2 →
Q9GZV7	—	0.938	Q9GZV7 →
Q13635	—	0.938	Q13635 →
Q9GM01	—	0.937	Q9GM01 →
Q9P0K9	—	0.937	Q9P0K9 →
Q02353	—	0.937	Q02353 →
Q61115	—	0.936	Q61115 →
Q9ESM3	—	0.936	Q9ESM3 →
B1AXV0	—	0.936	B1AXV0 →
GRM6	Metabotropic glutamate receptor 6	0.935	landscape →